Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Galecto, Inc.

DMRANASDAQ
Healthcare
Medical - Pharmaceuticals
$23.05
$4.91(27.07%)
U.S. Market opens in 5h 54m

Galecto, Inc. Fundamental Analysis

Galecto, Inc. (DMRA) shows weak financial fundamentals with a PE ratio of -1.84, profit margin of 0.00%, and ROE of -1.47%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position24.87%
PEG Ratio-0.23
Current Ratio3.73

Areas of Concern

ROE-1.47%
Operating Margin0.00%
We analyze DMRA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -149.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-149.0/100

We analyze DMRA's fundamental strength across five key dimensions:

Efficiency Score

Weak

DMRA struggles to generate sufficient returns from assets.

ROA > 10%
-1.48%

Valuation Score

Excellent

DMRA trades at attractive valuation levels.

PE < 25
-1.84
PEG Ratio < 2
-0.23

Growth Score

Weak

DMRA faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

DMRA maintains a strong and stable balance sheet.

Debt/Equity < 1
0.21
Current Ratio > 1
3.73

Profitability Score

Weak

DMRA struggles to sustain strong margins.

ROE > 15%
-147.05%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is DMRA Expensive or Cheap?

P/E Ratio

DMRA trades at -1.84 times earnings. This suggests potential undervaluation.

-1.84

PEG Ratio

When adjusting for growth, DMRA's PEG of -0.23 indicates potential undervaluation.

-0.23

Price to Book

The market values Galecto, Inc. at 4.37 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.37

EV/EBITDA

Enterprise value stands at -112.02 times EBITDA. This is generally considered low.

-112.02

How Well Does DMRA Make Money?

Net Profit Margin

For every $100 in sales, Galecto, Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-1.47 in profit for every $100 of shareholder equity.

-1.47%

ROA

Galecto, Inc. generates $-1.48 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.48%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

DMRA converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.84

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.23

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.37

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.21

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.73

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.47

vs 25 benchmark

ROA

Return on assets percentage

-1.48

vs 25 benchmark

ROCE

Return on capital employed

-1.46

vs 25 benchmark

How DMRA Stacks Against Its Sector Peers

MetricDMRA ValueSector AveragePerformance
P/E Ratio-1.8427.85 Better (Cheaper)
ROE-147.05%779.00% Weak
Net Margin0.00%-21544.00% (disorted) Weak
Debt/Equity0.21261.05 Strong (Low Leverage)
Current Ratio3.734.55 Strong Liquidity
ROA-147.58%-9957.00% (disorted) Weak

DMRA outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Galecto, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ